The inventor of Alirocumab is not a single individual, but rather a team of scientists at Regeneron Pharmaceuticals. Regeneron is credited with discovering and developing the drug, which is a PCSK9 inhibitor used to lower LDL cholesterol levels [1].
Who developed Alirocumab?
Regeneron Pharmaceuticals, Inc. developed Alirocumab. The company's research and development efforts led to the creation of this novel cholesterol-lowering medication [1].
What is Alirocumab used for?
Alirocumab is prescribed to reduce high levels of low-density lipoprotein (LDL) cholesterol in adults who have certain genetic conditions or established cardiovascular disease and have not achieved their LDL cholesterol goals with diet and other lipid-lowering therapies [2].
When did Alirocumab receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Alirocumab on July 24, 2015 [2].
What is the difference between Alirocumab and other cholesterol drugs?
Alirocumab belongs to a class of drugs called PCSK9 inhibitors. Unlike statins, which target the liver's cholesterol production, PCSK9 inhibitors work by blocking the PCSK9 protein, which prevents LDL receptors from being degraded. This allows more LDL receptors to remain on the surface of liver cells, clearing more LDL cholesterol from the blood [1].
When does Alirocumab's patent expire?
Patent expiration dates for Alirocumab can be complex due to multiple patents covering different aspects of the drug, including its composition of matter, methods of use, and manufacturing processes. Information on specific patent expiry timelines is often tracked by organizations like DrugPatentWatch.com [3].
Are there generic versions of Alirocumab available?
As of now, generic versions of Alirocumab are not yet available. Patent protections are in place, and the development of biosimilar versions typically follows after these patents expire or are successfully challenged [3].
What are the potential side effects of Alirocumab?
Common side effects of Alirocumab include injection site reactions (redness, itching, pain), upper respiratory tract infections, and flu-like symptoms [2]. More serious side effects are rare but can occur.
Who are Alirocumab's competitors?
The primary competitor to Alirocumab in the PCSK9 inhibitor class is Evolocumab, marketed by Amgen. Both drugs target the PCSK9 pathway to lower LDL cholesterol [1].
Sources:
1. Regeneron Pharmaceuticals, Inc.
2. U.S. Food and Drug Administration (FDA)
3. DrugPatentWatch.com